Health Robotics Reports 221 Net New Contracts in 2013 (232% of 2012’s Sales Bookings), with 51 Units in 4Q

Bozen, Sud-Tirol, Italy – January 7th, 2014

Health Robotics today reported FY2013 new sales of 69 Robots [20 for Oncology, and 49 for non-hazardous IVs and TPNs] or 177% of FY2012 Robot Sales Units, plus 152 i.v.SOFT workflow software contracts or 217% of FY2012 i.v.SOFT Sales Units. Revenue Bookings rocketed to 232% of FY2012, making 2013 yet another record year for the undisputed global Sterile (IV) Compounding Automation leader.

For 4Q2013, Health Robotics reported 51 net new installations under contract, including 18 I.V. Robots (2 for Chemotherapy, and 16 for non-hazardous IVs and TPNs) and 33 i.v.SOFT workflow software agreements, now reaching 530 worldwide installations,

Gaspar DeViedma, Health Robotics’ Executive Vice President, stated: “I’m very pleased with Health Robotics’ record-breaking 2013 performance, which reflects a healthy mix of additional Robot and IV workflow software sales to its pre-existing customers, as well as sales to net new Health-System pharmacies. Of particular significance in 2013 was the overwhelming market acceptance of 2nd Generation i.v.STATION ONCO by Pharmacy Directors in the USA, Canada, Europe, and Australia, winning 100% of public tender decisions over its global competitors1”.

During 4Q2013, Health Robotics and/or some of its global distributors signed 51 new purchase orders for: Albany Medical Center (NY), Duke University Cancer Center (NC), Fletcher Allen Health Care (VT), Maimonides Medical Center (NY), Penn Valley Forge (PA), Trinity Health-Saint Joseph Mercy (MI), SAHZ Haarlem (Netherlands), University of Maastricht (Netherlands), Hamad Medical (Qatar), and Su?leymaniye Dog?um ve Kad?n Hastanesi Eg?itim Aras? (Istanbul, Turkey).

Mr. DeViedma concluded: “i.v.STATION ONCO 2013’s success undeniably validates Health Robotics’ historical decision to divorce from Loccioni and the troubles caused by their old semi-automated robots that do not automatically cap nor auto-label chemotherapy doses. Many of Loccioni’s APOTECAchemo issues were widely exposed2 for their ongoing problems at the November 15th edition of the American Journal of Health System Pharmacy2. Auspiciously, Health-System

pharmacists continue to recognize the undeniable fact that Health Robotics’ second generation modular architecture of integrated and networked medical devices are fully-automated, with automatic labeling and tamper-resistant capping, offering 3 to 4 times faster speed/throughput, for less than half the price, size, and weight than its major competitors2, while delivering payback periods/R.O.I. ranging from 6 months for i.v.STATION to 1.5 years for i.v.STATION ONCO.“

Download in PDF Format :

Health Robotics – Pharma Tech PR Jan 7,2014

Contact Us Call Us